CCR8⁺ regulatory T cell depletion overcomes immune checkpoint blockade resistance in BRCA2-deficient prostate cancer
BRCA2-mutated prostate cancer is an aggressive, genomically unstable subtype, yet how this genomic instability influences tumor immunity remains undefined. We developed an isogenic, immunocompetent model of Brca2-deficient prostate cancer in which BRCA2 loss activated the cGAS/STING pathway and a type I interferon response across multiple cellular compartments, paradoxically leading to an overall immunosuppressed tumor microenvironment. Within this microenvironment, tumor-associated macrophages were interferon-responsive and expressed the CCR8 ligand Ccl8, and there was enrichment of immunosuppressive CCR8⁺ regulatory T cells (Treg). Anti-PD-1 monotherapy was ineffective and instead reinforced this immunosuppressive circuit, leading to expansion of CCR8⁺ Tregs. However, depletion of CCR8⁺ regulatory T cells overcame resistance to checkpoint blockade. Analysis of human BRCA2-mutated prostate cancer showed elevated CCR8 expression, supporting the translational relevance of the CCR8⁺ Treg axis as a potential therapeutic target in a disease largely refractory to immunotherapy.
Authors
- Elise Y. Cai (ORCID: https://orcid.org/0000-0002-2697-2508)
- X. G. Zhu
- Ramya Parameswaran
- Morgan E. Diolaiti (ORCID: https://orcid.org/0000-0001-5900-3060)
- Kimberly A. Rickman (ORCID: https://orcid.org/0009-0006-3427-620X)
- Alan Ashworth (ORCID: https://orcid.org/0000-0003-1446-7878)
- Harish N. Vasudevan (ORCID: https://orcid.org/0000-0001-9633-1100)
- Franklin W. Huang (ORCID: https://orcid.org/0000-0001-5447-0436)
- Irena Sun
- Christina Thai
- Yingyue Li
- Hanbing Song
- Valentina Rossi
- Nicole Ziper
Institutions
- San Francisco VA Medical Center (US)
- University of California, San Francisco (US)
- Tempus Labs (United States) (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-12
- DOI
- https://doi.org/10.64898/2026.11.11.765808
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- preprint